Explore innovative approaches and novel targets in analgesic medicine

The opioid crisis has cost the economy $1 trillion since 2001 in the USA alone, and the prospect does not look like it will get better any time soon. A recent study performed by Altarum suggests that the epidemic will cost the world economy an additional £750 billion over the next three years as death rates related to opioid drugs increase. The study indicates that the greatest financial costs result from lost earnings due to losses in productivity from young adults who would otherwise be in their prime working years, but have been impaired by substance abuse disorders, creating a cascading effect that damages the economy.*

SMi’s 18th Annual Pain Therapeutics Conference will pose particular focus on non-opioid analgesic targets, exploring mechanisms of action and providing insight on results obtained in clinical trials.

www.pain-therapeutics.co.uk/pharmaphorum

 

SPOTLIGHT on NON-OPIOID

 

With a focus on advancing a novel analgesic pipeline, SMi Group are delighted to welcome onto the agenda for 2018 expertise from:

 

  • Torsten Madsen, CMO, Aptinyx, who will present the Case Study on DEVELOPMENT OF NMDA RECEPTOR MODULATORS IN CENTRAL PAIN DISORDERS

 

  • Eric Nisenbaum, Head of Neurophysiology, Eli Lilly & Co with his presentation on SELECTIVE TARP-DEPENDENT AMPA RECEPTOR ANTAGONISTS AS A NOVEL THERAPY FOR CHRONIC PAIN

 

  • Iain Chessell, VP & Head, IMED Neuroscience, AstraZeneca with the Case Study on DRUGGING THE UN-DRUGGABLE: P2X4 MABS AS THERAPEUTICS FOR PAIN

 

Read more on these presentations and view full programme of the Pain Therapeutics conference website at www.pain-therapeutics.co.uk/pharmaphorum

 

WHO ELSE WILL HEAR FROM

Mundipharma | Amgen | Eli Lilly & Co | Danish Headache Centre |Innopain | Prescient Healthcare Group | Cara Therapeutics | Centrexion Therapeutics Corp. | Grunenthal GmbH | Ipsen | Lotus Clinical Research | MD Biosciences | Nektar Therapeutics | Janssen Pharmaceutical NV | Flexion Therapeutics | ViroMed | Novartis Pharmaceuticals

 

Download a brochure on the event website for a detailed conference agenda and full speaker line-up www.pain-therapeutics.co.uk/pharmaphorum

 

 

WHO WILL YOU MEET

 

With the event growing year on year, Pain Therapeutics 2018 will provide ample networking opportunites for our global audience of senior industry specialists. Recently joined companies: Semnur Pharmaceuticals | Orion Pharma | Asahi Kasei Corporation | Eupraxia Pharmaceuticals | Bayer AG | Arthritis Research UK | Premier Research | Pierre Fabre France

 

Take a look at last year’s attendee list on the event website to see who you could meet this May!

View more information on featured topics and speaker panel at www.pain-therapeutics.co.uk/pharmaphorum

 

Pain Therapeutics Conference on Twitter – @SMIpharm and #smipaintherapeutics

 

————————————————————————————————————-

Pain Therapeutics Conference | 21 – 22 May 2018 | London, UK www.pain-therapeutics.co.uk/pharmaphorum
————————————————————————————————————-